External quality assessment of noninvasive fetal RHD genotyping

Frederik Banch Clausen, Åsa Hellberg

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

3 Citeringar (SciVal)

Sammanfattning

Background and objectives: Fetal RHD genotyping of cell-free maternal plasma DNA from RhD negative pregnant women can be used to guide targeted antenatal and postnatal anti-D prophylaxis for the prevention of RhD immunization. To assure the quality of clinical testing, we conducted an external quality assessment workshop with the participation of 31 laboratories. Materials and methods: Aliquots of pooled maternal plasma from gestational week 25 were sent to each laboratory. One sample was fetal RHD positive, and a second sample was fetal RHD negative. A reporting scheme was supplied for data collection, including questions regarding the methodological setup, results and clinical recommendations. The samples were tested blindly. Results: Different methodological approaches were used; 29 laboratories used qPCR and two laboratories used ddPCR, employing a total of eight different combinations of RHD exon targets. Fetal RHD genotyping was performed with no false-negative and no false-positive results. One inconclusive result was reported for the RHD positive sample. All clinical conclusions were satisfactory. Conclusion: This external quality assessment workshop demonstrates that despite the different approaches taken to perform the clinical assays, fetal RHD genotyping is a reliable laboratory assay to guide targeted use of Rh prophylaxis in a clinical setting.

Originalspråkengelska
Sidor (från-till)466-471
Antal sidor6
TidskriftVox Sanguinis
Volym115
Utgåva5
Tidigt onlinedatum2020 mar 12
DOI
StatusPublished - 2020 jul

Ämnesklassifikation (UKÄ)

  • Klinisk laboratoriemedicin

Fingeravtryck

Utforska forskningsämnen för ”External quality assessment of noninvasive fetal RHD genotyping”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här